Alnylam Publishes Phase III ATTR-CM Data for Patisiran After FDA Rejection

Alnylam Pharmaceuticals on Wednesday announced that the results of the Phase III APOLLO-B study, assessing its investigational patisiran as a treatment for cardiomyopathy in transthyretin amyloidosis (ATTR), have been published in The New England Journal of Medicine.